Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.49 |
| ▸ | GRM5 | P41594 | 7/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707360 | 1.00 | PDK4 (0.53) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL22391820 | 0.95 | PDK4 (0.53) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL31342561 | 0.90 | PDK4 (0.50) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL31341979 | 0.86 | PDK4 (0.53) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL29197065 | 0.86 | PDK4 (0.53) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL1199843 | 0.85 | PDK4 (0.54) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL30112465 | 0.85 | PDK4 (0.54) | PDK4GRM1GRM5HTR6WDR5 | |
| SCHEMBL13993111 | 0.85 | GRM1 (0.57) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL9731949 | 0.85 | WDR5 (0.43) | WDR5JAK1CDK9CCNT1 | |
| SCHEMBL24670953 | 0.84 | PDK4 (0.51) | PDK4GRM1GRM5HTR6WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PDK4 3136/4885GRM1 1928/4885GRM5 1630/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | PDK4 1610/4885GRM1 2345/4885GRM5 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.